Company News

Sac-TMT is the first TROP2 ADC to improve OS and PFS compared to chemotherapy in patients with advanced or recurrent endometrial cancer who have progressed after platinum-based chemotherapy and anti-PD-1/L1 immunotherapy in a global Phase 3 study

Kelun-Biotech and Crescent Biopharma announce strategic partnership to develop and commercialize novel oncology therapeutics.

KLUS Pharma to attend the 16th World ADC San Diego summit from November 3-6, 2025.

Kelun-Biotech will present multiple clinical updates for key ADC programs at upcoming ESMO 2025 in Berlin, Germany from October 17-21.

Kelun-Biotech will present the results from six clinical studies at the 2025 ASCO Annual Meeting including for innovative TROP2 ADC, anti-PD-L1 antibody, and novel RET fusion inhibitor.

Kelun-Biotech recently receives IND clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for its innovative ADC drug SKB518.

Kelun-Biotech’s Radionuclide-Drug Conjugate (RDC) SKB107 receives IND approval from NMPA for clinical trials investigating the treatment of bone metastases in solid tumors.

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) is approved for marketing in its second indication of EGFRm NSCLC by the NMPA.

Study Results Abstracts for Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) will be presented at 2025 ASCO Genitourinary Cancers Symposium held in San Francisco from February 13-15, 2025.

Kelun-Biotech’s biosimilar product Cetuximab N01 Injection (达泰莱®, formerly A140) was approved for marketing by NMPA of China.

Kelun-Biotech’s tagitanlimab approved for marketing for second indication in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic NPC.

Kelun-Biotech's innovative ADC SKB445 receives IND approval from NMPA in China.

The second NDA for Kelun-Biotech's innovative HER2 ADC (trastuzumab botidotin) was formally accepted by the NMPA in China.

Kelun-Biotech's Anti-PD-L1 (Tagitanlimab, 科泰莱®) approved for marketing by NMPA of China for 3L+ nasopharyngeal carcinoma.

Kelun-Biotech’s TROP2 ADC Sacituzumab tirumotecan (sac-TMT, 佳泰莱®) approved for marketing by NMPA of China for 2L+ advanced or metastatic TNBC.

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA for locally advanced or metastatic EGFR-mutant NSCLC.

Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) were presented at 2024 CSCO Congress.

Positive results from multiple studies of Kelun Biotech's TROP2 ADC (Sac-TMT) in advanced solid tumors were presented at 2024 ESMO Congress.

Three study abstracts for sac-TMT (TROP2 ADC) to be presented at 2024 ESMO Congress.

Klus Pharma to attend ESMO Congress 2024 in Barcelona, Spain from Sept 13-17, 2024.

Klus Pharma to attend ADC & Radiopharmaceuticals Pharma and Biotech Partnering Summit in Boston, MA from Sept 9-10, 2024.

Klus Pharma to attend 15th Annual World ADC in San Diego from November 4-7th, 2024.

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA

Two abstracts of SKB264/sac-TMT (TROP2 ADC) were published at 2024 ASCO Annual Meeting to be held in Chicago from May 31 to June 4.

Kelun-Biotech and Ellipses A400 (EP0031) Cleared to Start Ph2 Clinical Development by US FDA

KLUS Pharma will attend 2024 BIO International Convention held in San Diego from June 3-6.

Kelun-Biotech will present the results from two clinical studies of SKB264/sac-TMT at the 2024 AACR Annual Meeting.

KLUS Pharma will attend the annual BIO-Europe Spring conference in Barcelona from March 18-20, 2024.

KLUS Pharma will attend the 14th World ADC conference in London from March 12-15, 2024.

KLUS Pharma will attend the AACR Annual Meeting in San Diego, CA from April 5-10, 2024.

Kelun-Biotech presented updated clinical results of SKB264 (MK-2870) in TNBC at 2023 SABCS.

A400/EP0031 is granted Orphan Drug designation by FDA for RET-fusion positive cancers

Selected for mini-oral presentation at 2023 ESMO: Kelun-Biotech to announce latest clinical study results of SKB264 (MK-2870, TROP2-ADC)

Kelun-Biotech officially debuts with HK$13.58 billion IPO on HKEX

CTA of Kelun-Biotech's TROP2-ADC (SKB264, MK-2870) in combination with pembrolizumab is approved in the European Union.

Kelun-Biotech will present results of Phase 2 study of SKB264 (TROP2 ADC) in metastatic NSCLC.

KLUS Pharma is attending 2023 ASCO Annual Meeting in Chicago from June 2-6th

KLUS Pharma will attend the BIO International Convention in Boston, MA from June 5-8, 2023.

KLUS Pharma will attend the 2023 AACR Annual Meeting in Orlando, Florida from April 14-19, 2023.

KLUS Pharma will attend 2023 Bio-Europe Spring live and virtual partnering events.

Merck and Kelun-Biotech announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.

A scientific poster of SKB264 will be presented at 2022 SABCS highlighting key data from Phase 2 TNBC study.

Come meet with us at BIO Partnering at JPM 2023 to learn more about our innovative pipeline!

KLUS Pharma is Attending BioPharm America in Boston from September 28-29

Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD

Kelun-Biotech's small molecule A400/EP0031 obtained IND approval from the FDA submitted by collaboration partner Ellipses Pharma

Clinical updates will be presented at 2022 ASCO for the Phase 1 dose-expansion study of A166 in HER2+ metastatic breast cancer.

KLUS Pharma will attend 2022 BIO International in San Diego from June 13-16.

KLUS Pharma will attend BIO-Europe Spring to be held virtually from March 28-31, 2022.

KLUS Pharma will attend the 40th Annual J.P. Morgan Health Care Conference to be held virtually from January 10-13, 2022

KLUS Pharma will attend 2021 BioPharm America Digital Conference held from September 20-23.

Kelun-Biotech will present an oral update on SKB264 at 2021 ESMO Annual Meeting held from September 16-21.

KLUS Pharma will attend BIO International Convention Digital 2021 from June 14-18.

Kelun-Biotech will attend and present at ASCO 2021 for A166, an anti-HER2 ADC.

Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and UK company Ellipses Pharma Ltd. Announce a Licensing Agreement for Innovative Small Molecule Cancer Therapeutics

KLUS Pharma will attend BIO-Europe Spring Digital Event held on March 22-25, 2021.

KLUS Pharma will attend BIO Partnering at JPM Digital Event held on January 11-15, 2021.

The IND for KL-A289, an anti-LAG-3 monoclonal antibody, was recently approved by the NMPA in China.

We are looking for partnerships to develop and distribute ACV200-17, a peptide drug to prevent COVID-19, in affected countries.

KLUS Pharma will present an update for SKB264, a novel TROP2 ADC, at BIO Digital Event held on June 8-12, 2020.

KLUS Pharma will present clinical update for our HER2 and TROP2 ADC programs at ASCO held on May 29-31, 2020.